Category Archives: Gene Therapy Clinics

Parkinsons Disease Treatment Market 2019- Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 – Instant…

Global Parkinsons Disease Treatment Market 2019-2025 Overview

The Parkinsons disease treatment market growth was driven because of increase in the geriatric population and the rise in the occurrence of the Parkinsons disease and the funding for research.

Global Parkinsons disease treatment market is anticipated to experience the substantial growth during the forecast period. Growth in the occurrence of the Parkinsons diseases is projected to supplement the growth of global Parkinsons disease treatment market in the coming future. In addition, the combined treatments supporting in the long action of constant dopaminergic stimulation medicines, neural transplantation and gene therapy is expected to fuel the Parkinsons disease treatment market growth.

Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/615

Parkinsons disorder is a neurological disorder affecting the movements of body. There are five stages of this disease and can hamper the individuals leg & hand movements, facial expressions getting worse with the growing age. Increase in the elderly population related to the rise in the investments in the activities of research & development, growth in the awareness for healthcare and the neurological disorders are the factors driving the global Parkinsons disease treatment market growth over the forecast period. On the other hand, due to the presence of the other treatments is hampering the Parkinsons disease treatment market growth.

Current developments in the Parkinsons disease treatment, for example, combined treatment to continue the effect of constant dopaminergic stimulation medicines, gene therapy, neural transplantation, neuroprotective treatment to reduce the disease prediction and support for the neurostimulation tools are estimated to provide large development in the global Parkinsons disease treatment market growth during the forecast period. Moreover, major characteristics that are fueling the requirement and demand for the global parkinsons disease treatment market are prevalence of parkinsons disease and growth in the geriatric population. Two important characteristics that are responsible to boost the Parkinsons disease treatment market development are prevalence of the neurodegenerative syndrome and rise in the elderly population. Although, increase in the medicines in the pipeline and growth in the R&D activities are anticipated to surge the Parkinsons disease treatment market size. In addition, lack of skills for the early diagnosis and large spending on treatment is projected to bolster the development of global Parkinsons disease treatment market.

Get Discount:https://www.adroitmarketresearch.com/contacts/discount/615

Key factor driving the growth of Parkinsons disease treatment market is the growth in the acceptance of the treatment for Parkinson disease in healthcare sector. For treating and detecting the dysfunctioning of the human beings central nervous system and the neurological damage because of lack of cells and nerves are the main function of Parkinsons disease treatment market.

Global Parkinsons disease treatment market is segmented into end-use, distribution channel, drug class and region. Based on end-use, market is divided into clinics and hospitals. On the basis of distribution channel, market is divided into retail pharmacies, online pharmacies and hospital. On considering the drug class, market is divided into MAO inhibitors, Levopoda/ Carbidopa and Dopamine Receptor Agonists.

Geographically, regions involved in the development of Parkinsons disease treatment market growth are Europe, North America and Asia Pacific. Asia Pacific is anticipated to show the rapid growth because of the increase in the trend of medical tourism and medical infrastructure. North America holds the largest

Read details of the report athttps://www.adroitmarketresearch.com/industry-reports/parkinsons-disease-treatment-market

Parkinsons disease treatment market share. Europe is dominating the Parkinsons disease treatment market because of the maximum market revenue in the coming years.

Key players involved in the Parkinsons disease treatment market analysis are Teva Pharmaceutical Industries, Novartis AG, Impax Laboratories and GlaxoSmithKline.

Key Segments in the Global Parkinsons Disease Treatment Market are-

By End-Use, market is segmented into:

By Distribution Channel, market is segmented into:

By Drug Class, market is segmented into:

By Regions market is segmented into:

What to expect from the Global Parkinsons Disease Treatment Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

Else place an Inquire before Purchase Parkinsons Disease Treatment Market Size, Status and Forecast 2025:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/615

About Us:

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Read the original post:
Parkinsons Disease Treatment Market 2019- Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 - Instant...

Cancer Biological Therapy Market Top Key Players, Size, Global Share, Trend, Segmentation, Demand, Opportunities And Forecasts To 2025 – Chronicle 99

The Report titled: Global Cancer Biological Therapy Market Analysis: Production, Capacity, Sales, Revenue, Trends, Revenue Share, and Forecast till 2025

The authors of the Cancer Biological Therapy Market Report have done extensive study of the global Cancer Biological Therapy market keeping in mind the key aspects such as growth determinants, opportunities, challenges, restraints, and market developments. This analysis will enrich the ability of the companies involved in the global Cancer Biological Therapy market to make precise decisions. The report also emphasizes on the current and future trends in the global Cancer Biological Therapy market, which may bode well for the global Cancer Biological Therapy market in the coming years.

Introduction:, Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. There are many biological therapies that have been approved and being used by various cancer specialists across the globe. While there are many other therapies also which are under the research and development phase and are yet to be available for commercial use., , , Biological therapy treatment is treatment process which is performed with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Most of the biological therapies uses bacteria or vaccines to mimic the bodys immune system to act against cancer developing cells. These various types of biological therapies, which are most of the times stated to biological response modifier therapy or immunotherapy, but these types of therapies do not always target cancer cells directly. Further there are other biological therapies like sections of genetic material or antibodies which are commonly known as DNA or RNA, do aim at targeting cancer cells directly. There are some other types of biological therapies that inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as cancer targeted therapies. , The Europe, Middle East and Africa Cancer Biological Therapy market is expected to reach US$ 29,776.3 million by 2023 at a CAGR of 5.0% during the forecast period., , , EMEA Cancer Biological Therapy Market is further segmented into type of therapy which include Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Cancer Growth Blockers, Interferons, Interleukins, Gene Therapy, Targeted Drug Delivery, Colony Stimulating Factor, Cancer Vaccines and other therapies. The Monoclonal Antibodies segment includes sub segment namely Naked Monoclonal Antibodies. Interferon segment is further sub segmented into Alpha Interferon, Beta Interferon and Gamma Interferon., , , On the basis on end users cancer biological therapy market is segmented into Hospitals & Clinics, Laboratories, Cancer Research Centers and other end users. Hospitals & Clinics accounted for the largest market share of EMEA cancer biological therapy market. Hospitals & Clinics commands maximum share of EMEA cancer biological therapy market in 2015. , On the basis of region, Europe accounted for the largest market share in biological therapy market. While Middle East and Africa region is expected to grow with a steady pace during forecast period.

Get Free Exclusive Sample of this Premium Report at @ https://www.esherpamarketreports.com/request-sample/es-193383/

Table of Contents:1. Research Methodology 2. Executive Summary 3. Market Overview 3.1. Definition 3.2. Industry Value Chain Analysis 3.3. Porters 5 Forces 3.4. Regulations 4. Market Dynamics 4.1. Introduction 4.2. Drivers 4.3. Constraints 4.4. Trends 5. Global Cancer Biological Therapy Market Segmentation, Forecasts and Trends by Application 6. Global Cancer Biological Therapy Market Segmentation, Forecasts and Trends by Technology 7. Global Cancer Biological Therapy Market Segmentation, Forecasts and Trends by Region 8. Competitive Intelligence 8.1. Company Market Share Analysis 9. Company Profiles 10. Investment Opportunities

Click Here For Detailed Table Of Contents

Enquire before purchasing this report @ https://www.esherpamarketreports.com/pre-order-enquiry/es-193383

Key Highlights of Cancer Biological Therapy Market Report:

Reasons To Buy:

Purchase this Report with Full Access @ https://www.esherpamarketreports.com/purchase/es-193383/

Contact Us:

Name: Jason George

Email: sales@esherpamarketreports.com

Call :USA: +1 408 757 0510

Organization: eSherpa Market Reports

About Us:

eSherpa Market Reports is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Here is the original post:
Cancer Biological Therapy Market Top Key Players, Size, Global Share, Trend, Segmentation, Demand, Opportunities And Forecasts To 2025 - Chronicle 99

Outlook on the Gene Therapy for CNS Disorders Market to 2025 by Application, – News by aeresearch

New Market Research Report on Gene Therapy for CNS Disorders Market size | Industry Segment by Applications (Hospitals, Clinics and Others), by Type (Ex Vivo and In Vivo), By Regional Outlook - Global Industry Analysis, Size, Share, Growth, Opportunity, Latest Trends, and Forecast to 2025.

Regional analysis is another highly comprehensive part of the research and analysis study of the global Gene Therapy for CNS Disorders market presented in the report. This section sheds light on the sales growth of different regional and country-level Gene Therapy for CNS Disorders markets. For the historical and forecast period 2020 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Gene Therapy for CNS Disorders market.

This report on Gene Therapy for CNS Disorders Material Market delivers an in-depth analysis that also comprises an elaborate assessment of this business. Also, segments of the Gene Therapy for CNS Disorders Material market have been evidently elucidated in this study, in addition to a basic overview pertaining to the markets current status as well as size, with respect to the profit and volume parameters.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/64581

Global market focusing on major players of Gene Therapy for CNS Disorders market:

This Gene Therapy for CNS Disorders Market Research/analysis Report Contains Answers to your following questions:

Market segmentation, by product types:

Market segmentation, by applications:

Highlights of Report:

An all-inclusive framework of the geographical terrain:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/64581

Read more here:
Outlook on the Gene Therapy for CNS Disorders Market to 2025 by Application, - News by aeresearch

Cancer Biological Therapy Market Size, Share, Technology, Included Features, Cost, Revenue, Manufacturers, Region, Applications and Forecast to 2025 -…

A new business intelligence Report Global Cancer Biological Therapy Marketis made covering in-depth analysis by manufacturers and key business segments. The report probes into the current trends, market drivers, growth opportunities, and restraints that are likely to impact the dynamics of the Cancer Biological Therapy Market over the forecast period 2020 2025. Cancer Biological Therapy Market Report presents a professional and deep analysis on the present state of Cancer Biological Therapy Market that Includes major types, major applications, Data type include capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export and etc. Industry chain, manufacturing process, cost structure, marketing channel are also analysed in this report.

Introduction:, Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. There are many biological therapies that have been approved and being used by various cancer specialists across the globe. While there are many other therapies also which are under the research and development phase and are yet to be available for commercial use., , , Biological therapy treatment is treatment process which is performed with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Most of the biological therapies uses bacteria or vaccines to mimic the bodys immune system to act against cancer developing cells. These various types of biological therapies, which are most of the times stated to biological response modifier therapy or immunotherapy, but these types of therapies do not always target cancer cells directly. Further there are other biological therapies like sections of genetic material or antibodies which are commonly known as DNA or RNA, do aim at targeting cancer cells directly. There are some other types of biological therapies that inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as cancer targeted therapies. , The Europe, Middle East and Africa Cancer Biological Therapy market is expected to reach US$ 29,776.3 million by 2023 at a CAGR of 5.0% during the forecast period., , , EMEA Cancer Biological Therapy Market is further segmented into type of therapy which include Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Cancer Growth Blockers, Interferons, Interleukins, Gene Therapy, Targeted Drug Delivery, Colony Stimulating Factor, Cancer Vaccines and other therapies. The Monoclonal Antibodies segment includes sub segment namely Naked Monoclonal Antibodies. Interferon segment is further sub segmented into Alpha Interferon, Beta Interferon and Gamma Interferon., , , On the basis on end users cancer biological therapy market is segmented into Hospitals & Clinics, Laboratories, Cancer Research Centers and other end users. Hospitals & Clinics accounted for the largest market share of EMEA cancer biological therapy market. Hospitals & Clinics commands maximum share of EMEA cancer biological therapy market in 2015. , On the basis of region, Europe accounted for the largest market share in biological therapy market. While Middle East and Africa region is expected to grow with a steady pace during forecast period.

Are You A Start-Up On The Way To Make It Vast? Grab an Free Exclusive Sample Copy of Cancer Biological Therapy Report Here @ https://www.esherpamarketreports.com/request-sample/es-193383/

Objective of Studies:

Cancer Biological Therapy Market Statistics by Types:

Cancer Biological Therapy Market Outlook by Applications:

Want To Institute Strategies For Upcoming Years? Our Reports Can Assist You To Plot Superior. Inquire Here @ https://www.esherpamarketreports.com/pre-order-enquiry/es-193383/

Key Question Answered in Report.

Reasons to Buy the Report:

Market Size Forecasts:The authors of the report have provided accurate estimation of the global Cancer Biological Therapy market size based on value and volumeMarket Trend Analysis:This section of the report throws light on the approaching trends and developments in the global Cancer Biological Therapy marketFuture Prospects:The report here offers crucial information on the rewarding opportunities in the global Cancer Biological Therapy marketRegional Analysis:Inclusive analysis of the potential regions and their countries in the global Cancer Biological Therapy market is provided in this part of the reportSegmental Analysis:Here, key segments comprising product type, application, and end user and their contribution to the overall market size are discussed in detailCompetitive Landscape:Market participants will get an overview of the business strategies considered by their competitors to stay ahead of the curve. This analysis will help the players to make informed business decisions in future.

Purchase this Report with Full Access & Complete TOC @ https://www.esherpamarketreports.com/purchase/es-193383/

Table of Contents:1 INTRODUCTION1.1 Definition1.2 Scope of Study1.2.1 RESEARCH OBJECTIVE1.2.2 ASSUMPTIONS & LIMITATIONS1.2.2.1 ASSUMPTIONS1.2.2.2 LIMITATIONS1.3 MARKET STRUCTURE:2 RESEARCH METHODOLOGY2.1 RESEARCH PROCESS:2.2 Primary Research2.3 SECONDARY RESEARCH:3 MARKET DYNAMICS3.1 DRIVERS3.1.1 GROWING Demand for newly developed Cancer Biological Therapy3.1.2 Growing trend of Outsourcing3.1.3 Growing Cancer Biological Therapy Industry in developing nations3.2 RESTRAINTS3.3 OPPORTUNITIES3.4 MACROECONOMIC INDICATORS4 MARKET FACTOR ANALYSIS4.1 Porters Five forces Model4.2 Bargaining power of suppliers4.3 BARGAINING POWER OF BUYERS4.4 THREAT OF NEW ENTRANTS4.5 Threat of Substitutes4.6 Intensity of Rivalry5 global Cancer Biological Therapy market, by Type6 global Cancer Biological Therapy market, By Application7 global Cancer Biological Therapy market, By Manufacturing Methods7.1 In-House Manufacturing7.2 Contract Manufacturing7.2.1 introduction8 Global Cancer Biological Therapy market, by region8.1 North America8.1.1 Introduction8.2 Europe8.2.1 Introduction8.3 Asia-Pacific8.3.1 introduction8.4 Middle East & Africa8.4.1 Introduction9 Competitive landscape9.1 Major Strategies adopted by market players9.1.1 STRATEGIC PARTNERSHIP9.1.2 Merger & Acquisition10 company profile

About Us:

eSherpa Market Reports is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Contact Us:

Name: Jason George

Email: sales@esherpamarketreports.com

Call :USA: +1 408 757 0510

Organization: eSherpa Market Reports

Click Here For Other Reports

Swimming Goggles Market By Application Analysis, Regional Outlook, Competitive Strategies And Forecast By 2025

world remotely operated vehicle rov Market 2020: Product Overview and Scope, Growth Rate and Price Analysis by Type, Forecast to 2025

Cooling Water Treatment Chemicals Market Analysis and In-Depth Research On Market Dynamics, Trends, Emerging Growth Factors and Forecasts to 2025

Read more from the original source:
Cancer Biological Therapy Market Size, Share, Technology, Included Features, Cost, Revenue, Manufacturers, Region, Applications and Forecast to 2025 -...

Global Age Related Macular Degeneration (AMD) Market: Industry Analysis and Forecast (2019-2026) – Expedition 99

Global Age Related Macular Degeneration (AMD) Marketwas valued US$ XX Bn in 2018 and is expected to reach XX Bn by 2026, at a CAGR of XX % during a forecast period.

Age-related macular degeneration is the prominent cause of severe, irreversible vision loss in people over age 60. It occurs when the small central portion of the retina deteriorates.

Growing population across the globe and the demography reflecting the predominance of the older population, the global affliction of AMD continues to increase at an unprecedented rate. The development of gene therapy for AMD, the growth in the geriatric population, and awareness concerning the AMD are some major factors behind the growth of the global age-related macular degeneration (AMD) market. Additionally, High prevalence of AMD is one of the key drivers in the global age-related macular degeneration (AMD) market. Factors like aging, smoking, high cholesterol, and high blood pressure are causing the prevalence of AMD.

On the other hand, high cost of the treatment, off label usage and strict regulatory policies are some of the factors, which are expected to limit the growth in the global age-related macular degeneration (AMD) market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/36109

The risk of the occurring the AMD is directly proportional to the age. With the number of people aged above 60 years, the prevalence of AMD is also growing. In 2017, there were, about XX Mn people in the age group 60 years over across the globe, and the number is projected to grow XX Bn during the forecast period. So, the geriatric population is growing faster than younger age groups.

Wet Age-related Macular Degeneration (WAMD) treatment is expected to contribute significant share in the Global Age-Related Macular Degeneration (AMD), market. For wet AMD treatment, the anti-vascular endothelial growth factor is commonly used, which helps to pause or delay the progression of visual loss. By delaying the action of VEGF chemical, it aids to prevent the condition from progressing and partially reverse it. Anti-VEGF medicines include Eylea, Lucentis and Avastin.

Region-wise, The Asia Pacific region is projected to be leading region in the Global age-related macular degeneration (AMD) market. The market in the Asia Pacific region is set to experience favourable growth, which is driven by factors like the elderly population & rising health care expenditure. An increase in the obese population and economic development are also expected to boost the growth in the age-related macular degeneration (AMD) market.

A rise in the number of pipeline drugs for age-related macular degeneration is facilitating the industry key players to sustain in the global age-related macular degeneration market. Additionally, fast track drug designations and regulator government policies like tax benefits are some of the prominent factors aiding the new key players to enter in the age-related macular degeneration market. For instance, Fovista, which is a product of Ophthotech received fast track designation by U.S. FDA and launched in 2018.

The objective of the report is to present comprehensive analysis of global age related macular degeneration (AMD) market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or

negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.The report also helps in understanding global age related macular degeneration (AMD) market dynamics, structure by analysing the market segments, and project the global age related macular degeneration (AMD) market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the global age related macular degeneration (AMD) market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/36109

The Scope of the Report for Global Age Related Macular Degeneration (AMD) Market

Global Age Related Macular Degeneration (AMD) Market, By Type

Dry Age-related Macular Degeneration (DAMD) Wet Age-related Macular Degeneration (WAMD)

Global Age Related Macular Degeneration (AMD) Market, By Drug

Lucentis Eylea Avastin Others

Global Age Related Macular Degeneration (AMD) Market, By Stages

Intermediate Stage Age Related Macular Degeneration Early-Stage Age Related Macular Degeneration Late Stage Age Related Macular Degeneration

Global Age Related Macular Degeneration (AMD) Market, By Route ofAdministration

Intravenous Intravitreal

Global Age Related Macular Degeneration (AMD) Market, By Age Group

Above 75 Year Above 60 Year Above 40 Year

Global Age Related Macular Degeneration (AMD) Market, By End User

Hospitals & Clinics Dignostic Centers Academic Research Institutes

Global Age Related Macular Degeneration (AMD) Market, By Region

North America Europe Asia Pacific Middle East & Africa South America

Key players operating in Global Age Related Macular Degeneration (AMD) Market

Kubota Pharmaceutical Holdings Co. Ltd. Alimera Sciences Inc. Adverum Biotechnologies Inc. Gilead Sciences Inc. Apellis Pharmeceuticals Inc. F. Hoffmann-La Roche Ltd. Allergan plc. Bausch Health Companies Inc. Regeneron Pharmaceuticals Inc. Neurotech Pharmaceuticals Inc. Ophthotech Corporation Novartis AG Pfizer Inc. GlaxoSmithKline plc. Bayer AG

Browse Full Report with Facts and Figures of Age Related Macular Degeneration Market Report at:https://www.maximizemarketresearch.com/market-report/global-age-related-macular-degeneration-amd-market/36109/

MAJOR TOC OF THE REPORT

Chapter One: Age Related Macular Degeneration Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Age Related Macular Degeneration Market Competition, by Players

Chapter Four: Global Age Related Macular Degeneration Market Size by Regions

Chapter Five: North America Age Related Macular Degeneration Revenue by Countries

Chapter Six: Europe Age Related Macular Degeneration Revenue by Countries

Chapter Seven: Asia-Pacific Age Related Macular Degeneration Revenue by Countries

Chapter Eight: South America Age Related Macular Degeneration Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Age Related Macular Degeneration by Countries

Chapter Ten: Global Age Related Macular Degeneration Market Segment by Type

Chapter Eleven: Global Age Related Macular Degeneration Market Segment by Application

Chapter Twelve: Global Age Related Macular Degeneration Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Here is the original post:
Global Age Related Macular Degeneration (AMD) Market: Industry Analysis and Forecast (2019-2026) - Expedition 99

UAB: 50 years of Improving Birmingham, Alabama and the World – Birmingham Times

UAB Magazine

Written by Charles Buchanan, Brett Bralley and Jay Taylor with editorial contributions from Matt Windsor and UAB Public Relations. Images from UAB Archives, Rachel Hendrix, Andrea Mabry, Sarah Parcak, Steve Wood and Getty Images. Web design by Tyler Bryant. Reprinted by permission of UAB Magazine.

UABs birth was like a ray of sunlight punching through the smog.

In 1969 the newly independent university, uniting a pioneering academic medical center and a growing extension center, brought the promise of a brighter future to a city eager for change.

Birmingham is better because of UAB. So are Alabama, America, and the world. In the following pages, discover some of the many ways that UAB has fulfilled its promiseby saving lives, solving problems, expanding knowledge, and opening doorsover 50 years.

1

Best of the best

UABs accolades shine a global spotlight on Birmingham and Alabama:

2

A way to retrain the brain

Most scientists once believed that neuroplasticitythe brains ability to grow or repair itselfended in childhood. But research by UAB neuroscientist Edward Taub, Ph.D., contributed to a shift in thinking, and in the 1990s he developed constraint-induced (CI) therapy for stroke patients with poorly functioning limbs. As the intensive training helps patients learn to accomplish tasks with their affected limbs, the brain adapts by strengthening communication with those parts of the body. And the results have been remarkable: Most patients see a clinically significant level of improvement in their ability to use their affected limbs, and brain scans have shown an increase in gray matter. Taub and UAB clinical psychologist Gitendra Uswatte, Ph.D., have used CI therapy to help thousands of stroke patientsand adapted it for patients impacted by cerebral palsy, traumatic brain injury, multiple sclerosis, and spinal cord injury. Today CI therapy is in use worldwide.

3

Discoveries on ice

UAB scientists conduct a lot of research in the fieldbut none may go as far afield as James McClintock, Ph.D.; Charles Amsler, Ph.D.; and Maggie Amsler. Their investigations take place at Palmer Station, Antarctica6,898 miles from their campus offices. For two decades, the biologists have led teams that dive into the frigid waters surrounding the icy continent to study the chemical ecology of the unique marine algae and invertebrates living there. What theyve discovered could aid the search for new drugs to help humans. The group also chronicles the dramatic impact of climate change, such as ocean acidification, on Antarctic marine life. You can see climate change happening there like no other place on earth, says McClintock.

4

A pinch of prevention

UAB endocrinologist Constance Pittman, M.D., turned her research passioniodines impact on thyroid functioninto a global mission. In the 1990s and 2000s, she teamed up with Kiwanis International and UNICEF to help eradicate iodine deficiency disorders (IDD), a prevalent cause of cognitive disabilities. Pittman traveled the world to convince companies to add iodine to table saltthe simplest solution for preventing IDD. And her work helped make a lasting impact.

5

Target: Diabetes

In 1973, UAB opened the nations first public diabetes hospitaland the first linked with an academic medical center. Today physicians on the front lines of the diabetes epidemic have an exciting new option to help their patients, thanks to breakthrough research from UABs Comprehensive Diabetes Center.

6

Sharing stories that matter

WBHM 90.3 FM radio went on the air in 1976 as the 200th National Public Radio (NPR)-affiliated station. A member-supported service of UAB, WBHM provides global news and award-winning local coverage to Birmingham and the surrounding region. The station also recently welcomed StoryCorps, an NPR-affiliated initiative, to collect stories from the Birmingham community that will be housed at the Library of Congress in Washington, D.C.

7

Book of Life

Its tough to find a physician anywhere in the world who hasnt learned a few things from Tinsley Harrison, M.D. The legendary School of Medicine cardiologist and dean created and edited Harrisons Principles of Internal Medicine, which has been reprinted 20 times, translated into 14 languages, and become arguably the most recognized book in all of medicine, according to the Journal of the American Medical Association.

8

Foresight

The School of Optometry has been a pioneer since it opened in 1969 as the nations first optometry school associated with an academic medical center. Three years later, it became the first optometry teaching program affiliated with a Veterans Administration (VA) hospital, establishing a national model. Today more than 2,500 optometry staff and students from various schools work in the VA system nationwide.

9

Helping our hometown

Living and working in the heart of the city, UAB students, faculty, and staff cant help but feel a connection to Birmingham. Here are just a few ways Blazers have volunteered to support their neighbors:

10

A whole new ball game

Gene Bartow Mens basketball coach1977-1996

UAB started a winning tradition in 1977 when it hired coach Gene Bartow away from powerhouse UCLA to start a mens basketball program. He created a legendary team able to topple top rivals and reach the NCAA Tournament in just its third seasonthe first of 15 NCAA Tournament and 12 National Invitational Tournament appearances on its record. As UABs first athletic director, Bartow also helped UAB compete in other arenas. Today student-athletes in 18 sports give Birmingham reasons to cheer. Take a spin through some of the Blazers most memorable moments:

11

New views of history

Its as if Indiana Jones and Google Earth had a love child. Thats how UAB anthropology faculty member and National Geographic fellow Sarah Parcak, Ph.D., described space archaeology to Stephen Colbert on The Late Show in 2016. She has pioneered the use of high-resolution satellite imagery to search for the buried remains of lost civilizations. And her discoveries have thrilled people worldwide, including Colbert. She was even mentioned in a Jeopardy! answer earlier this year.

12

Defense team

UAB immunologists have been among the first to shed light on the mechanisms powering our bodys defenses:

13

Game changers

Future football helmets may better protect athletes thanks to mechanical engineering professor Dean Sicking, Ph.D. (Before coming to UAB, he developed the lifesaving SAFER barriers used on NASCAR and IndyCar courses.) Analyzing data from thousands of helmet-to-helmet impacts in football, Sicking has developed designs for a new helmet that could address concussionsabsorbing as much energy of the impact as possible so that the athlete has less risk of brain injury.

14

The dividends of discovery

In 2018-2019, UAB received $602 million in research grants and awardsjust one year after surpassing the $500-million milestone for the first time. We are aiming high and exceeding our goals, and it is a testament to the UAB research communitys great ideas, hard work, and will to succeed, says Christopher Brown, Ph.D., vice president for research. A rise in research funding means more opportunities to explore the frontiers of knowledgebut it also enables UAB to attract top minds from around the country in health care, engineering, the sciences, and more, plus create new jobs that boost the local economy. Want to ensure that UAB continues its upward trajectory? Philanthropic support helps position the university to attain competitive research grants.

15

Giant leaps

Space is the place for UAB people and technology:

Researcher Larry DeLucas, O.D., Ph.D., became the first optometrist in orbit with a 1992 mission aboard the shuttle Columbia. There he conducted experiments to grow protein crystals, which give scientists a 3D view of protein structuresand a greater understanding of the roles they play in disease. DeLucas also served as chief scientist for the International Space Station in 1994-1995.

Astrophysicist Thomas Wdowiak, Ph.D., passed away in 2013, but his name lives onon Mars. The Red Planets Wdowiak Ridge honors the physics faculty members role in NASAs Mars Exploration Project. Wdowiak was in charge of operating the Mossbauer spectrometers onboard the Spirit and Opportunity rovers that helped uncover firm evidence that water once existed on Mars.

16

Focus on finances

Would you like to get better at saving, budgeting, or investing? Or do you dream of launching a business? The Regions Institute for Financial Education in the Collat School of Business has been helping people throughout the community develop practical, lifelong financial management skills since 2015. Some of its programs include a Money Math Camp for middle schoolers, a College Bridge Camp to prepare high schoolers for life after graduation, and for adults, a Do-It-Yourself Credit Repair Workshop.

17

Going green

Campus expansions have reshaped Birminghams Southside, and UAB works hard to be a good steward of that spaceand set a sustainable example. In 2008, UAB brought open green space into the heart of Birmingham by converting a city street into the Campus Green. Now UAB is aiming to reduce its greenhouse gas emissions by 20 percent and establish a clean energy standard of 20-percent renewable energy by 2025.

18

Ingenuity vs. Infection

Virus vanguards

Antiviral therapies are essential for treating everything from influenza to HIV. In 1977, UAB pediatrics experts Richard Whitley, M.D., and Charles Alford, M.D., helped spark the antiviral revolution by developing vidarabine, the first drug to treat encephalitis caused by the herpes simplex virus. In the 1990s, Whitley and his team transformed the herpes virus into a genetically engineered weapon against tumors.

Vaccines for everyone

The laboratory of Moon Nahm, M.D., is a national treasure, notes the National Institutes of Health. But its discoveries could help protect millions of children worldwide threatened by S. pneumoniae infections, the leading cause of pneumonia. (Nahms lab also is designated a World Health Organization Pneumococcal Reference Laboratory.) His mission is to make pneumonia vaccines more affordable for use in developing countries.

Global guardian

GeoSentinel is a worldwide network of clinics watching for potential pandemics in an increasingly interconnected world, ready to relay information quickly about new disease outbreaks and effective treatments. And it has Alabama roots. UAB travel medicine expert David Freedman, M.D., cofounded GeoSentinel, a collaboration between the International Society for Travel Medicine and the Centers for Disease Control and Prevention, in the 1990s. He also directed the network for 20 years.

19

Staying safe on the road

In 2002, UAB public health researchers unveiled the Digital Childa pioneering computer model evaluating the physical consequences of car crashes on young passengers at various stages of developmentto generate data that could lead to improved child safety devices. Shift gears to today, and researchers in UABs TRIP (Translational Research for Injury Prevention) Lab use virtual realitya first-of-its-kind SUV simulator built with Honda Manufacturing of Alabamato study distracted driving in an effort to save lives. The TRIP Lab also has a portable simulator for schools and community events to help educate students and others on the dangers of distracted driving.

20

A home for Birmingham history

Odessa WoolfolkEducator and civic leader

When Birmingham first dreamed of developing a civil rights museum and research center, UABs Odessa Woolfolk, then special assistant to the president and director of community relations, and Horace Huntley, Ph.D., a historian and first director of the African American studies program, helped lead efforts to turn that idea into a reality. The Birmingham Civil Rights Institute opened in 1992, with Woolfolk as president of its board of directors. Huntley also directed the institutes Oral History Project, which preserves the accounts of foot soldiers and other witnesses to the Birmingham campaign. Today the BCRI attracts visitors from around the world and is a key component of the Birmingham Civil Rights National Monument.

21

Invention in action

Faculty, staff, and students are designing the future for the rest of us. Preview some of their ingenious solutions:

Each year, biomedical engineering and business students develop technologies to help people overcome physical limitations. Examples include a joystick-controlled wheelchair for toddlerswhich won an international awardbuilt for the Bell Center for Early Intervention Programs, and a special scale to help wheelchair users monitor their weight, used by the Lakeshore Foundation. Another design, a mechanical umbrella to protect power wheelchair users from rainy weather, scored second place at the 2018 World Congress on Biomechanics.

Graphic design students in UABs Bloom Studio unleash their talents to support local nonprofits and underserved communities. You can spot their work on license plates and signs that promote and protect the Cahaba Riverpart of a collaboration with the Cahaba River Society.

Solution Studios pairs Honors College, engineering, and nursing students with UAB health professionals to tackle everyday problems affecting patient care. One team has designed a device prototype that could improve quality of life for patients wearing ostomy bags to expel waste. Another has focused on new, more comfortable methods of applying wires to the skin in settings such as intensive care units.

22

Spreading the word

Low literacy levels translate into increased high school dropout rates, a lower-performing workforce, and higher rates of social problems, say UAB School of Education experts. For years UABs Maryann Manning, Ed.D., led the charge to improve literacy across Alabama, launching programs such as a conference that attracted thousands of local schoolchildren to share their writing with authors and illustrators. Today the Maryann Manning Family Literacy Center continues her legacy, providing enrichment activities in reading, writing, math, arts, and science for children and helping teachers across Alabama learn innovative strategies to foster literacy skills in their classrooms.

23

The heart of innovation

John Kirklin, M.D.Surgery superstar

John Kirklin, M.D., helped put Birmingham on the medical map when he was recruited in 1966 to chair the Department of Surgery. He already was a superstar at the Mayo Clinic, where he had revolutionized cardiovascular surgery by improving the heart-lung machine and performing the first operations for a variety of congenital heart malformations. At UAB he continued to pursue new methods and techniques, such as the development of a computerized intensive care unit with continuous monitoring of vital functions, which became a model for ICUs worldwide.

When Kirklin passed away in 2004, colleagues estimated his medical innovations had saved millions of lives. And his legacy thrives in other ways: UAB is a world-class medical center in part because of Kirklins work behind the scenes, where he championed the combination of public and private investments to foster growth. His textbook, Cardiac Surgery, remains a must-read for anyone in the field. His name lives on in The Kirklin Clinic of UAB Hospital, which opened in 1992. And his son, cardiothoracic surgeon James Kirklin, M.D., directs UABs James and John Kirklin Institute for Research in Surgical Outcomes.

24

Birthplace of new businesses

UABs ideas and energy are an engine for entrepreneurship. The university was a founder of Birminghams Innovation Depot, where start-up companiessome born from UAB research breakthroughsfind the resources they need to grow. Today Innovation Depot is the Southeasts largest high-tech business incubator, home to more than 100 companies.

25

University of opportunity

In the fall of 2019, underrepresented students made up nearly 42 percent of UABs enrollment, and 20.5 percent of undergraduates were first-generation students. UAB has a long history of widening access to higher educationand potential careers in science and health careamong diverse students. Back in 1978, the Minority High School Research Apprentice Program began matching local students with faculty members for summer research experiences. Today, initiatives such as the Department of Surgerys Pre-College Internship for Students from Minority Backgrounds and the Neuroscience Roadmap Scholars program offer similar opportunities for students along their educational journeys.

26

Successful careers begin here

More than 135,000 alumni call UAB their alma mater. Today youll find them across the United States and around the world, working as leaders in health care, science, business, art, engineering, government, education, and other fields. Many stay connected with UAB through the National Alumni Society, which was established in 1979 and has 63 chapters in locations ranging from Washington, D.C., to Taiwan.

27

Read the original here:
UAB: 50 years of Improving Birmingham, Alabama and the World - Birmingham Times

Parkinsons Disease Treatment Market 2020 Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 – Science…

Global Parkinsons Disease Treatment Market 2020-2025 Overview

The Parkinsons disease treatment market growth was driven because of increase in the geriatric population and the rise in the occurrence of the Parkinsons disease and the funding for research.

Global Parkinsons disease treatment market is anticipated to experience the substantial growth during the forecast period. Growth in the occurrence of the Parkinsons diseases is projected to supplement the growth of global Parkinsons disease treatment market in the coming future. In addition, the combined treatments supporting in the long action of constant dopaminergic stimulation medicines, neural transplantation and gene therapy is expected to fuel the Parkinsons disease treatment market growth.

Request sample copy of Parkinsons Disease Treatment Market at: https://www.adroitmarketresearch.com/contacts/request-sample/615

Parkinsons disorder is a neurological disorder affecting the movements of body. There are five stages of this disease and can hamper the individuals leg & hand movements, facial expressions getting worse with the growing age. Increase in the elderly population related to the rise in the investments in the activities of research & development, growth in the awareness for healthcare and the neurological disorders are the factors driving the global Parkinsons disease treatment market growth over the forecast period. On the other hand, due to the presence of the other treatments is hampering the Parkinsons disease treatment market growth.

Current developments in the Parkinsons disease treatment, for example, combined treatment to continue the effect of constant dopaminergic stimulation medicines, gene therapy, neural transplantation, neuroprotective treatment to reduce the disease prediction and support for the neurostimulation tools are estimated to provide large development in the global Parkinsons disease treatment market growth during the forecast period. Moreover, major characteristics that are fueling the requirement and demand for the global parkinsons disease treatment market are prevalence of parkinsons disease and growth in the geriatric population. Two important characteristics that are responsible to boost the Parkinsons disease treatment market development are prevalence of the neurodegenerative syndrome and rise in the elderly population. Although, increase in the medicines in the pipeline and growth in the R&D activities are anticipated to surge the Parkinsons disease treatment market size. In addition, lack of skills for the early diagnosis and large spending on treatment is projected to bolster the development of global Parkinsons disease treatment market.

Get Discount:https://www.adroitmarketresearch.com/contacts/discount/615

Key factor driving the growth of Parkinsons disease treatment market is the growth in the acceptance of the treatment for Parkinson disease in healthcare sector. For treating and detecting the dysfunctioning of the human beings central nervous system and the neurological damage because of lack of cells and nerves are the main function of Parkinsons disease treatment market.

Global Parkinsons disease treatment market is segmented into end-use, distribution channel, drug class and region. Based on end-use, market is divided into clinics and hospitals. On the basis of distribution channel, market is divided into retail pharmacies, online pharmacies and hospital. On considering the drug class, market is divided into MAO inhibitors, Levopoda/ Carbidopa and Dopamine Receptor Agonists.

Geographically, regions involved in the development of Parkinsons disease treatment market growth are Europe, North America and Asia Pacific. Asia Pacific is anticipated to show the rapid growth because of the increase in the trend of medical tourism and medical infrastructure. North America holds the largest

Read details of the report athttps://www.adroitmarketresearch.com/industry-reports/parkinsons-disease-treatment-market

Parkinsons disease treatment market share. Europe is dominating the Parkinsons disease treatment market because of the maximum market revenue in the coming years.

Key players involved in the Parkinsons disease treatment market analysis are Teva Pharmaceutical Industries, Novartis AG, Impax Laboratories and GlaxoSmithKline.

Key Segments in the Global Parkinsons Disease Treatment Market are-

By End-Use, market is segmented into:

By Distribution Channel, market is segmented into:

By Drug Class, market is segmented into:

By Regions market is segmented into:

What to expect from the Global Parkinsons Disease Treatment Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

Else place an Inquire before Purchase Parkinsons Disease Treatment Market Size, Status and Forecast 2025:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/615

Read more:
Parkinsons Disease Treatment Market 2020 Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 - Science...

What can hold back the hands of time? Scientists have looked at these five treatments – Ottawa Citizen

Scientists have been researching ways to increase a humans healthspan and possible lifespan for decades. Here are things they have considered, and what they have learned.

The intervention:Rapamycin

What is it? First identified in the 1970s in a soil sample from Easter Island, this FDA-approved drug is used to suppress the immune system in transplant patients. Counterintuitively, it also appears to boost immune function in healthy animals. Rapamycin may reduce inflammation, which increases with age. One study found that rapamycin rejuvenated the hearts of old mice. After treatment, there were significant improvements to cardiac function. Research with mice has also found that even when they where administered rapamycin late in life, the mice still had improvements to lifespan and their healthspan.

The verdict: Geroscientist Matt Kaeberlein said rapamycin shows the most promise of any drug that targets aging, in his opinion, although he doesnt necessarily think rapamycin will increase lifespan by 20 to 30 years on average in people. Although it might at the right dose. I do think theres reason to believe that rapamycin could improve several age-related health problems, including boosting immune function and protecting against dementia, cancers, and heart disease.

But critics say it is unclear what the downstream effects could be. If you take a compound like that for a few decades, there may be downstream effect a small epidemic of lymphoma, perhaps, said geriatrician Dr. Peter Boling. While it is approved to prevent rejection in organ transplant patients, it is not approved to treat aging.

There are also questions about side effects, which may include susceptibility to infection and the possibility of developing lymphoma.

We still dont know about all of the hidden dangers. As hopeful as we might be, we have to be aware of the limitations, said Boling.

The intervention: Metformin

What is it? This drug has been prescribed to millions of people to treat diabetes. Among other effects, it decreases insulin levels. It also appears to target biological mechanisms related to aging. Its anti-aging effects may be linked to its influences on metabolic and cellular processes associated with inflammation. It has been linked to lifespan extension and protection against age-related diseases in animal models.

The verdict: The speculation in scientific circles has been that many of the drugs used to treat early-stage chronic disease may be effective, at least in part, because they target aging itself.

Metformin is an interesting case, said Kaeberlein. It clearly increases survival in people with diabetes and likely would do the same for pre-diabetics and others with significant metabolic disease, which represents a growing percentage of adults, he said. However, its less clear whether metformin will be beneficial in people who are metabolically healthy and exercise regularly.

The studies in mice suggest that metformin is different from rapamycin, in the sense that metformin only increases lifespan by a very small amount and in some cases has been reported to have no effect or even shortens lifespan in mice.

The FDA has accepted a clinical trial, Targeting Aging with Metformin, known as TAME, which will test whether metformin can delay the onset of age-related diseases and conditions including cancer, cardiovascular disease and Alzheimers disease. The goal of the trial, which is estimated to cost $55 million, is not to help people live to be 120 years old but to add health to our years, said the American Federation for Aging Research.

Like metformin, several promising drugs show great potential and await trials. If successful, the TAME trial would give the pharmaceutical industry impetus to advance these drugs and transform aging from a period of sickness to a time of extended vitality.

The intervention: Caloric restriction

What is it? A dietary regimen that reduces calories while maintaining nutrients. Research in lab animals, which started almost a century ago, has shown that it is possible to delay age-related diseases in mice and rats through dietary and caloric restriction, but results have varied.

A parallel study of two groups of rhesus monkeys, one at the University of Wisconsin and the other at the U.S. National Institute on Aging, looked at the life-prolonging and health effects of a calorie-restricted diet. The researchers found that the Wisconsin monkeys on a diet with 30 per cent fewer calories than the control group survived to about 28 years for males and about 30 years for females a couple of years above average for monkeys in captivity. Calorie-restricted monkeys in both groups showed fewer age-related health conditions compared to the control monkeys.

Some biohackers people who use biological interventions to optimize health have embarked on caloric restriction diets, with the goal of living longer. Entrepreneur Dave Asprey, author of Bulletproof Diet, has said he plans to live to be 180 and is hacking his own biology with a number of interventions, including supplements and a strict diet.

The verdict so far: The rhesus monkey study also produced some contradictory findings. The National Institute on Agings study found that while the dieting monkeys showed improved health, they didnt necessarily live longer than the control monkeys. Its not clear why there was a difference between the two groups of monkeys, although they were fed different diets and had different feeding times and access to food. The ages at which they dieted may also have come into play.

There is no compelling evidence caloric restriction will work with people, said Doug Gray, a molecular biologist with an interest in the role of protein homeostasis in aging and diseases of aging at the Ottawa Hospital Research Institute.

If this sounds like a depressing route to extreme longevity, even scientists agree. Noted one researcher: Life might seem longer, but it wouldnt necessarily be longer.

The intervention: Gene editing

What is it? Genome editing, or gene editing, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced.

Last February, for example, the journal Nature Medicine reported on a therapy using CRISPR-Cas9 genome editing technology aimed at suppressing rapid aging in mice with the rare genetic disorder progeria, which causes accelerated aging. According to the report, two months after the therapy, the progeria mice were stronger and more active and had better heart health. Their lifespan also increased by about 25 per cent.

The verdict so far: Not ready for prime time, said Boling. Even though we have successfully mapped the human genome, and its technically possible to remove a gene sequence and replace it, we have yet to successfully edit genes in a complex organism. Many people dont want to eat food containing genetically-modified organisms, let alone become one, he said.

I dont think we have a clear handle on a special gene sequence that would essentially change the aging process. I would want to see if we could do it in a limited and focused way without undue downstream consequences.

In 2017, researchers at Stanford University medical school reported that injections of blood plasma from donors between the ages of 18 and 30 showed promise for helping human Alzheimers patients with mild to moderate symptoms regain some ability to perform basic daily tasks.Colleen De Neve Colleen De Neve / Calgary Herald

The intervention: Young blood

What is it? There have been a number of studies that looked at whether giving old mice blood from young mice could reverse some signs of aging. Even the researchers admitted it sounded creepy, but the results were intriguing. One study at the University of California, Berkeley, published in 2018, found that old mice showed benefits, including better muscle repair, from receiving blood from young mice. But young mice who received old blood had negative effects, including performing poorly on a strength test.

In 2017, researchers at Stanford University medical school reported that injections of blood plasma from donors between the ages of 18 and 30 showed promise for helping human Alzheimers patients with mild to moderate symptoms regain some ability to perform basic daily tasks, such as remembering to take their medications or preparing meals. The results were based on reports from the patients and their caregivers. The researchers cautioned that more research is needed, since the trial involved only nine patients who had received plasma infusions and nine who had received a placebo saline infusion.

The verdict so far: Dont try it. In a statement last February, the FDA said it had significant public health concerns about establishments that offer infusions of plasma from young donors to treat conditions ranging from normal aging and memory loss to Parkinsons disease, multiple sclerosis, Alzheimers disease, and PTSD.

Simply put, were concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies. Such treatments have no proven clinical benefits for the uses for which these clinics are advertising them and are potentially harmful, warned the FDA. There are reports of bad actors charging thousands of dollars for infusions that are unproven and not guided by evidence from adequate and well-controlled trials.

Read the original here:
What can hold back the hands of time? Scientists have looked at these five treatments - Ottawa Citizen

Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2018-2026) – Bulletin 99

Global Cell Therapy Technologies Market was valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South America

Key players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at:https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Continued here:
Global Cell Therapy Technologies Market : Industry Analysis and Forecast (2018-2026) - Bulletin 99

MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich’s Ataxia – P&T Community

NEW YORK and GAINESVILLE, Fla., Jan. 13, 2020 /PRNewswire/ --The Muscular Dystrophy Association (MDA) and AavantiBio, a biotechnology company developing a gene-targeting therapy for Friedreich's ataxia (FA), today announced the award of MDA Venture Philanthropy (MVP) funding totaling $1,076,232 to advance AavantiBio's phase 2 clinical trial of a gene-replacement therapy for the disease.

MVP is MDA's drug development program, which is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular disorders. MVP evaluates and makes targeted investments in for-profit and not-for-profit companies and academics developing therapeutics.

FA is a rare, hereditary disease that causes damage to parts of the spinal cord and brain, and there is currently no cure. AavantiBio was founded with the aim of developing an effective treatment for the disease and improving the lives of FA patients.

"With the approval of several first-time gene-targeting therapies for neuromuscular diseases over the past several years, including the first-ever gene-replacement therapy for spinal muscular atrophy, our community should have much to hope for as more and more therapies continue to be developed," says Lynn O'Connor Vos, MDA's president and CEO. "MDA is thrilled to be a part of the quest to help further develop the first gene-targeting therapy for the treatment of Friedreich's ataxia. By partnering with AavantiBio, together we can address the unmet need faced by patients who live with this genetic disease, for which there are still no treatments and no cures."

Co-founders Manuela Corti, PT, PhD, assistant professor of Pediatrics at the University of Florida, Gainesville, and Barry Byrne, MD, PhD, associate chair of Pediatrics and director of the Powell Gene Therapy Center at UF, started working with the FA community five years ago and are thrilled about their new partnership with MDA.

"This is a great opportunity for AavantiBio, and we're thankful to the MDA for their generous contribution," Dr. Corti says. "We hope to strengthen our collaboration as we work together on this project."

Dr. Corti and Dr. Byrne aim to include both adults and children who have FA in their clinical trials, paving the way for new solutions.

"We're delighted to take the next step in fulfilling our commitment to patients and families living with FA based on this investment from MDA," Dr. Byrne says. "We're looking forward to initiating screening for the first clinical study and a pivotal study in FA before the end of the year. The endorsement and investment from the MDA will be key to our programmatic growth."

MDA's investment will help accelerate AavantiBio's mission and begin production of the clinical gene vector for its therapy program. Clinical trials are expected to begin in 2020.

Dr. Corti was previously awarded an MDA research grant to develop and test a gene-replacement therapy in a mouse model of FA. With the current funding, AavantiBio will sponsor a study at the University of Florida led by Sub Subramony, MD, professor of Neurology. The clinical trial will assess changes in neurological and cardiac function in patients with FA treated with both intravenous (systemic) and intrathecal (into-the-spine) injections of the company's gene-replacement therapy for the mutated FXN gene.

About Friedreich's ataxia

FA is a mitochondrial disease. Mutations in the frataxin gene (FXN) lead to decreased production of the frataxin protein, resulting in diminished energy production in cells, including those of the nervous system and heart. FA's major neurological symptoms include muscle weakness and ataxia, or a loss of balance and coordination. FA mostly affects the spinal cord and the peripheral nervesthat connect the spinal cord to the body's muscles and sensory organs, but it can also affect the cerebellum (causing ataxia) and heart. The prevalence of FA has been estimated at 1 in every 50,000 individuals worldwide. Symptoms typically begin between the ages of 5 and 15 years, and the rate of progression varies from person to person. There currently are no effective cures or treatments for FA.

About AavantiBio

Founded in 2017 and based inGainesville, Fla., AavantiBio is a biotechnology companyfounded on the vision of creating the first effective treatment for FA. The company's gene-replacement therapy approach uses an adeno-associated virus (AAV) vector to deliver a functional copy of the FXN gene to a patient's cells.

The co-founders bring more than 30 years of research experience in the field of neuromuscular disease, including their current work focusing on FA. Dr. Corti has more than 10 years of research experience in gene therapy approaches for the treatment of Duchenne muscular dystrophy and Pompe disease. Dr. Byrne has made significant contributions to theunderstanding and treatment of Pompe disease. He was previously awarded nearly $2 million in MDA funding to conduct foundational research in developing and testing AAV vectors in animal models of muscular dystrophy, and he was the first to show that AAV vectors are able to effectively express therapeutic genes in striated muscle cells.

About the Muscular Dystrophy Association

MDA is committed to transforming the lives of people affected by muscular dystrophy, ALS, and related neuromuscular diseases. We do this through innovations in science and innovations in care. As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than $1 billion since our inception to accelerate the discovery of therapies and cures. Research we have supported is directly linked to approved, life-changing therapies across multiple neuromuscular diseases. We support the largest network of multidisciplinary clinics providing best-in-class care at more than 150 of the nation's top medical institutions, and each year thousands of children and young adults learn vital life skills and gain independence at MDA Summer Camp and through recreational programs. For more information visitmda.org.

View original content to download multimedia:http://www.prnewswire.com/news-releases/mda-awards-venture-philanthropy-funding-of-more-than-1m-to-aavantibio-to-develop-gene-targeting-therapy-for-friedreichs-ataxia-300985256.html

SOURCE Muscular Dystrophy Association

Read the rest here:
MDA Awards Venture Philanthropy Funding of More Than $1M to AavantiBio to Develop Gene-Targeting Therapy for Friedreich's Ataxia - P&T Community